Vanguard Global Advisers
GENB

Vanguard Global Advisers’s Generate Biomedicines GENB Stock Holding History

Vanguard Global Advisers’s Portfolio GENB Stock Details GENB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$187K Buy
11,088
+9,863
+805% +$134K ﹤0.01% 2522
2026
Q1 		$15.3K Buy
+1,225
New +$15K ﹤0.01% 3392

Other funds holding GENB

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Global Advisers's GENB Position: Q2 2026 in Review

Vanguard Global Advisers increased its Generate Biomedicines (GENB) stake by 805% in Q2 2026, buying an estimated $134K and bringing the position to 11,088 shares worth $187K. The position accounts for ﹤0.01% of the portfolio, ranked #2522.

Vanguard Global Advisers first reported a position in GENB in Q1 2026 and has held it in 2 quarters since. 81 funds tracked by Wall St. Rank hold GENB as of Q2 2026.

  • Vanguard Global Advisers held 11,088 shares of Generate Biomedicines worth $187K as of Q2 2026.
  • Vanguard Global Advisers bought 9,863 Generate Biomedicines shares in Q2 2026, an estimated $134K.
  • Generate Biomedicines made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2522 holding.
  • Vanguard Global Advisers first reported a position in Generate Biomedicines in Q1 2026 and has held it in 2 quarters since.
  • 81 funds tracked by Wall St. Rank held Generate Biomedicines as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.